As insurers and PBMs prepared to submit their comments about a proposed overhaul of the prescription drug rebate system, CMS on April 5 issued a guidance document aimed at mitigating at least some of their concerns. While that memo had a mixed reception among industry players and analysts, it does seem to make clear that the administration is not backing down on its goal of implementing the proposed rule by Jan. 1, 2020.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.